Deutsche Bank issued a report on Valeant Pharma (NYSE:VRX), dropping its stock price target to $29.00 today
- Updated: October 14, 2016
In a statement issued on 10/14/2016 Deutsche Bank dropped the price target of Valeant Pharma (NYSE:VRX) from $30.00 to $29.00 reporting a potential upside of 0.27%.
On 10/12/2016, RBC Capital reported about Valeant Pharma (NYSE:VRX) bumped down the target price from $36.00 to $35.00 that suggested an upside of 0.53%.
Yesterday Valeant Pharma (NYSE:VRX) traded -1.76% lower at $22.77. VRX’s 50-day average is $26.86 and its two hundred day average is $26.89. With the last stock price close down -16.80% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same time. 8,367,051 shares of the stock were exchanged, down from an average trading volume of 22,608,000
See Chart Below
With a total market value of $0, Valeant Pharma has with a 52 week low of $18.55 and a 52 week high of $179.83 .
In addition to Deutsche Bank reporting its target price, a total of 18 firms have reported on the stock. The consensus target price is $43.56 with 3 firms rating the stock a strong buy, 2 brokers rating the stock a buy, 10 brokers rating the stock a hold, 4 brokers rating the stock a underperform, and finally 1 equity analyst rating the company a sell.
Brief Synopsis About Valeant Pharma (NYSE:VRX)
Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, CeraVe, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.